METHOCARBAMOL
Clinical safety rating
safeAnimal studies have demonstrated safety
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism of action is not fully understood. It is thought to produce skeletal muscle relaxation by depressing the central nervous system, possibly via general CNS depression, without directly affecting the neuromuscular junction or skeletal muscle fibers.
| Metabolism | Metabolized by the liver via dealkylation and hydroxylation. The major metabolic pathway involves O-dealkylation to form a glycinate conjugate, with CYP450 enzymes likely involved. |
| Excretion | Renal: primarily as glucuronide conjugates and unchanged drug (~50-70% as metabolites, <2% unchanged). Fecal: minimal, <2%. Biliary: not significant. |
| Half-life | Terminal elimination half-life: 1-2 hours. Clinical context: short half-life necessitates frequent dosing (q6h) for sustained muscle relaxation. |
| Protein binding | Protein binding: 46-50% to albumin. |
| Volume of Distribution | Volume of distribution: 0.6-0.8 L/kg. Clinical meaning: distributes widely into tissues, moderate Vd indicating extravascular distribution. |
| Bioavailability | Oral: high bioavailability, ~80-100% (well absorbed with first-pass metabolism to inactive conjugates). Intravenous: 100%. |
| Onset of Action | Oral: onset within 30 minutes. Intravenous: immediate (within minutes). |
| Duration of Action | Oral: 4-6 hours. Intravenous: 2-4 hours. Clinical notes: effects are dose-dependent and shorter with higher clearance. |
| Molecular Weight | 241.24 |
METHOCARBAMOL 1500 mg orally 4 times daily or 750 mg orally every 4 hours, or 1-3 g intravenously every 8 hours, not to exceed 3 g/day intravenously for more than 3 consecutive days.
| Dosage form | TABLET |
| Renal impairment | CrCl <50 mL/min: Administer every 8-12 hours; CrCl <30 mL/min: Administer every 12 hours; hemodialysis: Supplementation not well-defined; avoid if possible due to propylene glycol content. |
| Liver impairment | Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Contraindicated. |
| Pediatric use | Not recommended for children under 16 years; safety and efficacy not established. |
| Geriatric use | Start at lower end of dosing range (e.g., 750 mg orally 4 times daily) due to increased risk of sedation and falls; monitor renal function and adjust accordingly. |
| 1st trimester | Limited human data; animal studies show no evidence of fetal harm. Use only if clearly needed. |
| 2nd trimester | No known risks; use cautiously. Skeletal muscle relaxant effects may affect maternal coordination. |
| 3rd trimester | Avoid near term due to potential neonatal muscle weakness and respiratory depression. |
Clinical note
CNS depressants may enhance sedative effects Can cause discoloration of urine.
| Placental transfer | Crosses placenta in animal studies; human data limited. Expected to cross due to molecular weight <500 Da. |
| Breastfeeding | Excreted into breast milk in small amounts; unlikely to cause adverse effects in infant. Monitor for sedation and poor feeding. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Animal studies show fetal abnormalities (reduced fetal weight, skeletal ossification delays) at doses 1-3 times human dose; no adequate human studies. Second and third trimesters: Potential for neonatal CNS depression and hypotonia if used near term. Avoid use unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal vital signs, level of consciousness, and neuromuscular function. Fetal monitoring for heart rate variability and movements if used near term. Assess neonatal tone and respiration if used at delivery. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies show no impairment of fertility at therapeutic doses. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Drowsiness |
| Serious Effects |
Hypersensitivity to methocarbamolMyasthenia gravisComa or pre-coma statesBrain damageRenal failure with anuria
| Precautions | May cause dizziness, drowsiness, or blurred vision; caution with activities requiring mental alertness. Use with caution in patients with hepatic impairment, renal impairment, or myasthenia gravis. Avoid concurrent use with other CNS depressants. May cause urine discoloration (brown, black, or blue). |
| Food/Dietary | No significant food interactions. Grapefruit juice does not affect methocarbamol. However, avoid alcohol entirely due to additive CNS depression. |
| Clinical Pearls | Methocarbamol is a centrally acting muscle relaxant with sedative properties. Avoid or taper to prevent rebound muscle spasm. Monitor for CNS depression, especially when combined with alcohol or other CNS depressants. Use cautiously in elderly due to fall risk. May cause urine discoloration (brown, black, or blue-green) which is benign. Onset of action is within 30 minutes; maximal effect in 1-2 hours. Typical adult dose: 1.5-2 g PO QID for first 2-3 days, then 1 g QID. |
| Patient Advice | Take exactly as prescribed; do not increase dose or frequency without consulting your doctor. · This medication may cause drowsiness, dizziness, or blurred vision. Do not drive, operate machinery, or perform hazardous tasks until you know how it affects you. · Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may increase sedation and risk of falls. · Notify your healthcare provider if you experience fever, rash, itching, or jaundice (yellowing of skin/eyes). · Urine may turn brown, black, or blue-green; this is harmless and not a cause for alarm. · Do not stop suddenly; gradual dose reduction is recommended to prevent withdrawal symptoms like muscle spasm or anxiety. · If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose. |
Loading safety data…